{"code":"M1412","short_description":"Met nsclc w\/ egfr alk oth ab","long_description":"Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1\/2\/3 gene fusion, met ex14 skipping mutation, and ret rearrangement","status":"active","section":"M-codes: Medical Services","category":"Medical Services","effective_date":"2025-01-01","termination_date":null,"replacement_code":"","opps_status_indicator":"M","opps_status_label":"Items \/ services not billable to the fiscal intermediary or MAC","opps_apc":"","fee_schedules":[],"mue":[],"drug_classes":[],"ndc_crosswalk":[],"utilization":[],"urls":{"self_html":"https:\/\/hcpcslookup.com\/codes\/m1412","self_json":"https:\/\/hcpcslookup.com\/api\/codes\/M1412.json"}}